Emergent BioSolutions (EBS) Tops Q4 EPS by 46c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.34 --0%
Revenue Growth %: -45.6%
Financial Fact:
Earnings per share - diluted: 0.45
Today's EPS Names:
PHAR, EEFT, INIO, More
Revenue Growth %: -45.6%
Financial Fact:
Earnings per share - diluted: 0.45
Today's EPS Names:
PHAR, EEFT, INIO, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $0.05, $0.46 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $194.7 million versus the consensus estimate of $243.33 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Independent Bank (IBCP) Misses Q3 EPS by 11c
- Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens - 'Weakness a Buying Opportunity'
- JetBlue Airways (JBLU) Misses Q3 EPS by 6c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
